Skip to content

The role of pentoxifylline in erythropoietin-resistant anemia

Evalution the role of pentoxifylline in erythropoietin-resistant anemia in hemodialysis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20100413003698N2
Enrollment
60
Registered
2018-07-09
Start date
2018-04-04
Completion date
Unknown
Last updated
2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney dialysis. Y84 Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Interventions

Intervention 1: Intervention group: pentoxifylline. Each patient in the trial group will receive received PTX (400mg twice a day for 12 weeks). Intervention 2: Control group: control group will recei

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: having the age of 18 years and more receiving HD treatments at least for 3 months receiving 4-hour HD treatments 3 times per week a hemoglobin (Hb)<11 in at least 2 consecutive tests in a month no change in EPO dose for at least 1 month before starting the study.

Exclusion criteria

Exclusion criteria: blood transfusion due to any reason in recent 3 months

Design outcomes

Primary

MeasureTime frame
Hemoglobin. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn to measure of hemoglobin.

Secondary

MeasureTime frame
Erythrocyte sedimentation rate. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn.;C-reactive protein. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Pakfetrat

Shiraz University of Medical Sciences

pakfetratm@sums.ac.ir+98 71 3647 4332

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026